Cogent Biosciences, Inc. — Director's Dealing 2019

Apr 11, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Unum Therapeutics Inc. (UMRX)
CIK: 0001622229
Period of Report: 2019-03-01

Reporting Person: WILSON CHARLES (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-01	Stock Option (Right to Buy)	$4.36	A	174400	Acquired	2029-03-01	Common Stock (174400)	Direct

Footnotes

F1: 25% of the shares vests on March 1, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.